Skip to search formSkip to main contentSkip to account menu

farglitazar

An L-tyrosine derived and peroxisome proliferator-activated receptor (PPAR) agonist with hypoglycemic and lipid lowering activity. Farglitazar shows… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

GI 262570

Broader (2)

OxazolesTyrosine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The Degradation Chemistry of Farglitazar and Elucidation of the Oxidative Degradation Mechanisms.
2015
2015
Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein-Tyrosine Phosphatase 1B Inhibition.
A novel series of 2,7-substituted 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and biologically… 
2010
2010
Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).
2010
2010
Farglitazar lacks antibrotic activity in patients with chronic hepatitis C infection
Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor… 
2009
2009
Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-gamma ligands: potential positron emission tomography imaging agents.
2008
2008
Double blind, randomized, placebo-controlled, multi-center,phase II dose ranging study to assess the antifibrotic activityof farglitazar in chronic hepatitis C infection.
2007
2007
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
Peroxisome proliferator-activated receptor gamma (PPAR&ggr;) agonists are highly effective in the treatment of type 2 diabetes… 
Highly Cited
2004
Highly Cited
2004
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Loss-of-function mutations in the ligand-binding domain of human peroxisome proliferator-activated receptor gamma (PPARgamma) are… 
2002
2002
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses, which has been… 
2001
2001
Proxies for insulin resistance are associated with dyslipidaemia in a randomized controlled trial of farglitazar [Abstract]
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)